Diagnostic Accuracy of Capnography in Nasogastric Tube Placement

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05817864
Collaborator
(none)
390
1
30
13

Study Details

Study Description

Brief Summary

A prospective observational diagnostic study will be conducted to assess the sensitivity and specificity of using capnography in detecting the correct placement of nasogastric tubes using the reference standards of radiography and measurement of aspirates for pH value.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Capnography

Detailed Description

A prospective observational diagnostic study will be conducted. Patients ≥ 18-year-old and requiring the insertion of an nasogastric tube will be recruited using a convenience sampling method from general medical and geriatric wards, intensive care units (ICUs), accident and emergency departments (AEDs), and subacute/rehabilitation/infirmary wards in 21 acute or subacute/convalescent/extended care hospitals. End-tidal carbon dioxide (ETCO2) detection by sidestream capnography, which indicates airway intubation of an nasogastric tube when a capnogram waveform or an ETCO2 level > 10 mmHg, will serve as the index test. The reference standards will be the pH value of gastric content aspiration (pH ≤ 5.5 indicates gastric placement) and X-ray performed after the index test. Each participant will be included only once. Sensitivity, specificity, positive predictive value, and negative predictive value, and the area under the receiver operating characteristic curve of capnography will be calculated to assess the diagnostic performance of capnography. The variability in diagnostic accuracy in participants with different characteristics will be compared. The time spent and the cost of the index test and the reference test will be compared.

This study will provide evidence on the diagnostic accuracy of capnography in verifying nasogastric tube placement and inform the update of clinical practice guidelines and stakeholders' decisions regarding the adoption of ETCO2 detection as a routine method for verifying nasogastric tube placement.

Study Design

Study Type:
Observational
Anticipated Enrollment :
390 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Accuracy of Using Capnography in Verification of Nasogastric Tube Placement in Hospital Settings
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Observational group

All participants included will be in one observational cohort.

Diagnostic Test: Capnography
Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level > 10 mmHg. Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement.

Outcome Measures

Primary Outcome Measures

  1. Sensitivity of Capnography [Through study completion, an average of 2 year]

    True Positive / (True Positive + False Negative) × 100%

  2. Specificity of Capnography [Through study completion, an average of 2 year]

    True Negative / (True Negative + False Positive) × 100%

  3. Positive Predictive Value of Capnography [Through study completion, an average of 2 year]

    True Positive / (True Positive + False Positive) × 100%

  4. Negative Predictive Value of Capnography [Through study completion, an average of 2 year]

    True Negative / (True Negative + False Negative) × 100%

  5. Overall diagnostic performance of Capnography [Through study completion, an average of 2 year]

    Measured by the area under the receiver operating characteristic curve (AUROC). The test accuracy level is considered high when the AUROC value is ≥ 0.9.

Secondary Outcome Measures

  1. Difference in the time spent of index test and reference test [Through study completion, an average of 2 year]

    Compare the time spent of index test (i.e., capnography) and reference test (i.e., radiography)

  2. Difference in the cost of index test and reference test [Through study completion, an average of 2 year]

    Compare the cost of index test (i.e., capnography) and reference test (i.e., radiography)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years old or above;

  • Admitted to the general medical and geriatric wards, ICUs, or subacute/rehabilitation/infirmary wards in subacute/convalescent/extended care hospitals or visiting AEDs in acute hospitals;

  • Requiring the insertion of an nasogastric tube into the stomach for assessment, nutritional support and medication administration during the study period.

Exclusion Criteria:
  • Participants receiving life-saving intervention at the time of recruitment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Chinese University of Hong Kong Hong Kong Hong Kong SAR China

Sponsors and Collaborators

  • Chinese University of Hong Kong

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Chau Pak Chun Janita, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05817864
Other Study ID Numbers:
  • 2022073
First Posted:
Apr 18, 2023
Last Update Posted:
Apr 18, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Chau Pak Chun Janita, Professor, Chinese University of Hong Kong

Study Results

No Results Posted as of Apr 18, 2023